|
15/08/2025
|
07:00
|
Third Patient Treated with HG-CT-1 CAR-T Therapy
|
RNS
|
|
31/07/2025
|
07:00
|
Total Voting Rights
|
RNS
|
|
29/07/2025
|
08:00
|
Placing to Raise £250,000 and Director’s Dealing
|
RNS
|
|
16/07/2025
|
07:00
|
Hemogenyx Awarded Grant
|
RNS
|
|
30/06/2025
|
07:00
|
Total Voting Rights
|
RNS
|
|
17/06/2025
|
07:00
|
Clearance to Proceed with Pediatric Expansion
|
RNS
|
|
03/06/2025
|
14:02
|
Placing to Raise £451,250 and Director’s Dealing
|
RNS
|
|
03/06/2025
|
07:00
|
Second Patient Passes Initial Safety Tests
|
RNS
|
|
30/05/2025
|
15:14
|
Total Voting Rights
|
RNS
|
|
29/05/2025
|
14:06
|
Result of AGM
|
RNS
|
|
14/05/2025
|
07:00
|
Pediatric Amendment to Clinical Protocol
|
RNS
|
|
13/05/2025
|
07:00
|
AGM Correction
|
RNS
|
|
08/05/2025
|
07:00
|
Placing to Raise £451,250 and Director’s Dealing
|
RNS
|
|
02/05/2025
|
16:24
|
Notice of AGM
|
RNS
|
|
02/05/2025
|
07:00
|
Second Patient Treated with HG-CT-1 CAR-T Therapy
|
RNS
|
|
28/04/2025
|
07:00
|
Final Results
|
RNS
|
|
03/04/2025
|
07:00
|
FDA Annual Report
|
RNS
|
|
31/03/2025
|
07:00
|
Total Voting Rights
|
RNS
|
|
24/03/2025
|
07:00
|
First Patient Safety
|
RNS
|
|
17/03/2025
|
07:00
|
Recruitment of Second Patient for Clinical Trials
|
RNS
|
|
13/03/2025
|
15:10
|
Conversion of convertible loan notes
|
RNS
|
|
11/03/2025
|
07:00
|
Institutional investment
|
RNS
|
|
24/02/2025
|
07:00
|
First-in-Human Treatment with HG-CT-1
|
RNS
|
|
19/02/2025
|
16:50
|
Issue of convertible loan notes
|
RNS
|
|
31/01/2025
|
09:35
|
Total Voting Rights
|
RNS
|
|
08/01/2025
|
07:00
|
Placing to raise £340,000
|
RNS
|
|
02/01/2025
|
07:00
|
Change of Company Secretary and Registered Office
|
RNS
|
|
31/12/2024
|
07:00
|
Total Voting Rights
|
RNS
|
|
30/12/2024
|
07:00
|
Opening of First Clinical Site
|
RNS
|
|
19/12/2024
|
07:00
|
Ultrafast CAR-T Manufacturing
|
RNS
|
|
10/12/2024
|
16:10
|
Admission of New Ordinary Shares and New ISIN
|
RNS
|
|
09/12/2024
|
13:30
|
Result of Extraordinary General Meeting
|
RNS
|
|
09/12/2024
|
07:00
|
Site Initiation Visit Completed
|
RNS
|
|
06/12/2024
|
07:00
|
CBR Macrophage Delivery Update
|
RNS
|
|
29/11/2024
|
07:00
|
Total Voting Rights
|
RNS
|
|
22/11/2024
|
12:49
|
Notice of Extraordinary General Meeting
|
RNS
|
|
22/11/2024
|
07:00
|
IRB Approval for Phase I Clinical Trial
|
RNS
|
|
11/11/2024
|
07:00
|
Institutional Investment
|
RNS
|
|
30/10/2024
|
07:00
|
Schedule for Phase I Clinical Trial Opening
|
RNS
|
|
02/10/2024
|
11:19
|
Strategic Investment from Prevail Partners, LLC
|
RNS
|
|
27/09/2024
|
07:00
|
Half-year Report
|
RNS
|
|
09/09/2024
|
07:00
|
FLT3 Assay Ready for Phase I Trials at MD Anderson
|
RNS
|
|
02/09/2024
|
07:00
|
CDX Development Update
|
RNS
|
|
28/08/2024
|
07:00
|
Presentation at CBD S&T Conference
|
RNS
|
|
27/06/2024
|
16:39
|
Result of Annual General Meeting
|
RNS
|
|
17/06/2024
|
07:00
|
Operations Update
|
RNS
|
|
03/06/2024
|
07:00
|
Posting of Annual Report & Notice of AGM
|
RNS
|
|
25/04/2024
|
07:00
|
Final Results
|
RNS
|
|
28/03/2024
|
07:00
|
Total Voting Rights
|
RNS
|
|
29/02/2024
|
07:00
|
Placing to Raise US$4.2 million
|
RNS
|